

Pemigatinib (PEMAZYRE)

Criteria for Use

February 2022

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the [PBM INTERnet](#) or [PBM INTRAnet](#) site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive Pemigatinib.

- Care not provided by a VA or VA Community Care provider of hematology/oncology services
- Unmanageable CYP3A inhibitor/inducer drug interaction identified
- Clinically significant corneal or retinal disorder identified by ophthalmologic exam
- Serum phosphate level greater than ULN
- Untreated, clinically unstable brain and/or CNS metastases
- Pregnancy (i.e. known pregnancy or positive pregnancy test)
- Breastfeeding

Inclusion Criteria

All of the following must be fulfilled in order to meet criteria:

- Diagnosis of advanced/metastatic or surgically unresectable cholangiocarcinoma
- Documented disease progression after at least one prior systemic therapy
- Confirmed tumor expression of FGFR2 fusion or select rearrangement by FDA-approved next generation sequencing
- Baseline ophthalmology exam, including optical coherence tomography (OCT), performed
- Goals of care and role of Palliative Care consult have been discussed and documented.
- ECOG* Performance Status 0-2

* ECOG=Eastern Cooperative Oncology Group; FGFR2=Fibroblast growth factor receptor 2

Prepared: October 2020. Jonathan Solis, Pharm.D. Candidate and John Malamakal, Pharm.D., MS, BCPS, BCOP of the South Texas Veterans Health Care System Updated: March 2022

Contact person: Berni Heron, Pharm.D., BCOP. National PBM Clinical Pharmacy Program Manager, Formulary management, VA Pharmacy Benefits Management Services
